paclitaxel

P2, N=146, Active, not recruiting, Queen Mary University of London | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2021 --> Aug 2026

Troxerutin (TXR) is a bioflavonoid with demonstrated cardioprotective properties in various cardiac injury models, including cardioprotective effects in doxorubicin-induced myocardial injury, as well as diabetic myocardiopathy. Importantly, TXR did not abrogate the anticancer activity of PXT in cultured human MDA-MB cells. In conclusion, TXR hindered the cardiotoxicity of PXT and showed cardioprotective effects via its inhibitory actions on ER stress, ferroptosis, oxidative stress, and apoptosis.

P1, N=45, Active, not recruiting, University of Oklahoma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Sep 2025

Our study reveals that H. pylori contribute to gastric carcinogenesis by activating the B4GALT5/YWHAZ/FOXO3a axis via specific glycosylation, suggesting YWHAZ N95 glycosylation as a potential therapeutic target for GC.

Here, we show that the release of HMGB1 by tumor cells is required for the combinatorial efficacy with TIM-3 blockade observed with paclitaxel, docetaxel, fluorouracil, and irradiation. Instead, STING activation promotes endoplasmic reticulum (ER) stress and lysosomal exocytosis, driving HMGB1 secretion. Thus, non-canonical STING signaling in response to taxanes can promote the efficacy of chemoimmunotherapy.

P2, N=42, Recruiting, University College Hospital, Ibadan | Trial completion date: Aug 2023 --> Aug 2030 | Trial primary completion date: Mar 2023 --> Mar 2027

P1, N=30, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2034 --> Mar 2035 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Apr 2030

P2/3, N=168, Active, not recruiting, Compass Therapeutics | Completed --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

Despite adjuvant carboplatin, paclitaxel, and bevacizumab followed by maintenance therapy, she developed platinum-resistant progression with peritoneal and nodal disease and is currently receiving additional systemic therapy with poor response. This case highlights the potential for malignant transformation in benign-appearing SCT-NOS and underscores the importance of counseling patients on the rare risk of recurrence and the need for novel therapeutic strategies in recurrent disease. Integration of clinical, pathologic, and molecular data may improve risk stratification and management of this rare tumor.

Consistent with these subtype-specific features, CS1 tumors exhibited distinct sensitivities to dasatinib, lapatinib, paclitaxel, and cisplatin, indicating immune-state-associated therapeutic vulnerabilities. Together, these findings suggest a RUNX1-associated immunosuppressive tumor ecology in UVM and provide a conceptual framework for immune-state-guided therapeutic strategies.

P3, N=660, Recruiting, Genmab | Trial completion date: Feb 2029 --> Nov 2029 | Trial primary completion date: Nov 2028 --> Aug 2029

P3, N=782, Active, not recruiting, NRG Oncology | Trial primary completion date: Oct 2026 --> Dec 2025